MiNK Therapeutics (NASDAQ:INKT) Price Target Cut to $4.00 by Analysts at Robert W. Baird

MiNK Therapeutics (NASDAQ:INKT) had its target price reduced by Robert W. Baird from $8.00 to $4.00 in a research report released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of MiNK Therapeutics in a report on Wednesday, October 9th.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock opened at $0.70 on Friday. MiNK Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $1.90. The stock has a fifty day moving average of $0.73 and a two-hundred day moving average of $0.85. The company has a market capitalization of $27.48 million, a price-to-earnings ratio of -1.78 and a beta of 0.05.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.